Direct Somatic Cell Conversion to Hepatocytes via Transcription Factors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional methods for differentiating hepatocytes from embryonic or pluripotent stem cells are inefficient, ethically challenging, and pose safety risks, while existing cell resources for drug screening, such as mouse-derived hepatocytes, are not human-relevant and have limitations in proliferation and drug metabolism functions.
Innovation Solution
A composition and method for direct conversion of somatic cells into induced hepatic stem cells, hepatocytes, and cholangiocytes using specific direct conversion factors like OCT4, HNF4α, NR4A2, NR4A1, TBX3, NR5A1, NR5A2, and NR0B2 proteins or their nucleic acids, introduced via vectors, to bypass the need for pluripotent stem cells and improve efficiency and safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional methods using embryonic stem cells or pluripotent stem cells are used to differentiate hepatocytes, then hepatocyte production is possible, but the process is inefficient, ethically challenging, and time-consuming
Solution Approach 1:
The patent extracts and eliminates the intermediate pluripotent stem cell stage from the conventional differentiation pathway. By directly converting somatic cells into hepatocytes using specific transcription factors (HNF4A, CEBPA, FOXA2, GATA4, GATA6, PAX8, SOX9), the method bypasses the time-consuming embryonic stem cell establishment and pluripotent stem cell reprogramming steps, achieving direct hepatocyte production with significantly improved efficiency and reduced time loss
Solution Approach 2:
Instead of following the conventional forward pathway of embryonic stem cells → pluripotent stem cells → differentiated hepatocytes, the patent inverts the approach by directly reprogramming somatic cells into hepatocytes through the introduction of hepatocyte-specific transcription factors. This reverse engineering approach eliminates ethical concerns associated with embryonic stem cells and achieves rapid hepatocyte production without intermediate stages
2Reliability
If conventional methods using pluripotent stem cells are used, then hepatocyte differentiation is possible, but safety is not secured due to teratoma formation risk and insufficient cell numbers
Solution Approach 1:
The patent removes the pluripotent stem cell intermediate stage that is responsible for teratoma formation risk. By directly converting somatic cells into functional hepatocytes without passing through pluripotent states, the method eliminates the safety hazard of undifferentiated cell proliferation while simultaneously achieving sufficient cell numbers for therapeutic applications through efficient direct reprogramming
Solution Approach 2:
The patent uses somatic cells as disposable starting material that can be directly converted into functional hepatocytes without the need for expensive and time-consuming pluripotent stem cell culture maintenance. The direct conversion method produces sufficient numbers of functional cells for therapy while avoiding the safety risks associated with long-term pluripotent cell culture
3Adaptability or versatility
If mouse-derived primary culture hepatocytes are used for drug screening, then cell resources are available, but they are not human-relevant and cannot verify drug effects accurately
Solution Approach 1:
The patent changes the species parameter from mouse to human by using human somatic cells as the starting material for direct conversion. This parameter change ensures that the resulting hepatocytes are human-derived and physiologically relevant for drug screening, allowing accurate verification of drug effects on human liver metabolism while maintaining the versatility needed for various drug screening applications
4Measurement precision
If human-derived primary culture hepatocytes are used, then human-relevance is achieved, but proliferation and maintenance of function in vitro are difficult
Solution Approach 1:
The patent uses somatic cells as a renewable, easily obtainable starting material that can be directly converted into functional hepatocytes. This approach replaces the difficult-to-maintain primary human hepatocytes with a more sustainable system where somatic cells serve as disposable precursors that can be continuously converted into functional hepatocytes for drug screening, ensuring both human-relevance and adequate cell supply
Data Source
AI summary
The present invention relates to a composition for inducing direct conversion from a somatic cell into one or more kinds selected from the group consisting of an induced Hepatic stem cell (iHSC), a hepatocyte, and a cholangiocyte, and a method of direct conversion of a somatic cell into one or more kinds selected from the group consisting of an induced Hepatic stem cell, a hepatocyte, and a cholangiocyte.